On Monday, Alkermes plc (NASDAQ: ALKS) opened higher 4.21% from the last session, before settling in for the closing price of $28.86. Price fluctuations for ALKS have ranged from $21.75 to $32.88 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 10.61%. Company’s average yearly earnings per share was noted 82.69% at the time writing. With a float of $158.77 million, this company’s outstanding shares have now reached $166.98 million.
Considering the fact that the conglomerate employs 2100 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 82.31%, operating margin of 20.77%, and the pretax margin is 22.07%.
Alkermes plc (ALKS) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Alkermes plc is 1.87%, while institutional ownership is 109.74%. The most recent insider transaction that took place on Nov 06 ’24, was worth 309,169. In this transaction EVP R&D, Chief Medical Officer of this company sold 10,471 shares at a rate of $29.53, taking the stock ownership to the 99,238 shares. Before that another transaction happened on Nov 06 ’24, when Company’s Officer proposed sale 10,471 for $29.53, making the entire transaction worth $309,169.
Alkermes plc (ALKS) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 82.69% per share during the next fiscal year.
Alkermes plc (NASDAQ: ALKS) Trading Performance Indicators
Check out the current performance indicators for Alkermes plc (ALKS). In the past quarter, the stock posted a quick ratio of 3.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.22. Likewise, its price to free cash flow for the trailing twelve months is 15.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.96, a number that is poised to hit 0.75 in the next quarter and is forecasted to reach 1.84 in one year’s time.
Technical Analysis of Alkermes plc (ALKS)
Compared to the last year’s volume of 1.84 million, its volume of 2.04 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 85.60%. Additionally, its Average True Range was 0.98.
During the past 100 days, Alkermes plc’s (ALKS) raw stochastic average was set at 97.09%, which indicates a significant increase from 95.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.82% in the past 14 days, which was higher than the 35.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $27.69, while its 200-day Moving Average is $26.55. Nevertheless, the first resistance level for the watch stands at $30.61 in the near term. At $31.15, the stock is likely to face the second major resistance level. The third major resistance level sits at $32.01. If the price goes on to break the first support level at $29.22, it is likely to go to the next support level at $28.36. Now, if the price goes above the second support level, the third support stands at $27.82.
Alkermes plc (NASDAQ: ALKS) Key Stats
There are currently 161,803K shares outstanding in the company with a market cap of 4.85 billion. Presently, the company’s annual sales total 1,663 M according to its annual income of 355,760 K. Last quarter, the company’s sales amounted to 378,140 K and its income totaled 92,380 K.
